By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal second quarter 2025 results through the filing of its Form 10-Q. Since our previous update, the company has made progress with its multiple GLP-1 trials, received patent awards in epilepsy and shared its strategy for advancing its development … Read more
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Update on the DrugSorb-ATR Regulatory Process Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, that their Medical Device License application to Health Canada was in advanced review, and that they continue to expect regulatory decisions in … Read more
By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) reports 2024 results highlighting several achievements including progress on its HARMONIC, LP-184 and LP-284 trials, a portfolio of expedited designations in multiple indications and advances in the RADR platform with modules that offer predictive algorithms for blood brain barrier (BBB) … Read more
By Brian Lantier, CFA NASDAQ:VIOT READ THE FULL VIOT RESEARCH REPORT On Tuesday, March 25th, Viomi Technology (NASDAQ:VIOT) released its second half and full year for 2024. As a result of the company’s divestiture of its IoT business in August 2024, the company is a pure-play home water systems and home appliance company. Importantly, the … Read more
By Thomas Kerr, CFA NASDAQ:SDOT READ THE FULL SDOT RESEARCH REPORT 4th Quarter and Full Year 2024 Financial Results On March 11, 2025, Sadot Group (NASDAQ:SDOT) reported 4th quarter and full year 2024 results which showed continued strength in the commodity trading business. In the latest filings, the restaurant operations have been reported as discontinued … Read more